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The majority of soft tissue mass is composed of muscle and fatty tissue. As adipose
tissue makes up about twenty percent of the body weight, it seems obvious that one of
the most common soft tissue sarcomas (STS) is liposarcoma (LPS) [1,2,3,4]. However,
LPS originate from primitive mesenchymal cells rather than mature fat cells. In fact,
these tumors are rare in the subcutaneous fat, a common location of lipomas, and they
are most frequently located in deeper structures [3]. Although LPS are one of the most
common STS, accounting for 10-20% of all STS [1,2,3,4], there are only limited recent
data that address epidemiological and treatment related aspects of this entity. Usually,
these data are embedded in reports on sarcoma in general, which seems not advisable
because the biological behavior and prognosis of LPS seems to be different from most
other STS [3,5]. Furthermore, there are strong indications that biological subtype deter-
mines the outcome in LPS [6,7]. This diversity in clinical behavior may not become
apparent if LPS are reviewed together with other STS. The purpose of the present study
was to gain an insight into epidemiological aspects of LPS, to evaluate treatment results
and to determine prognostic factors for local recurrence, metastasis, disease-free and
disease-specific survival.
Patients and methods
All consecutive liposarcomas that were diagnosed at the Groningen University Hospital,
from October 1977 to January 2000, were reviewed regarding the clinicopathological
data, treatment, and follow-up. Patients were followed clinically at the Groningen Uni-
versity Hospital for a maximum period of 10 years. Data were retrospectively collected by
chart review. For patients who were no longer being followed, data had to be collected by
correspondence with the referring physician. Histopathologically, all tumors were re-
viewed, and if necessary revised, by one pathologist with special interest and experience
in STS (WMM). Patients with perioperative signs of regional and/or distant metastatic
disease (AJCC stage IV) and those, in whom the LPS could not be resected completely
(R2-resection), were excluded from the study.
The extent of diagnostic preoperative work up has changed during the last decades. Cur-
rently, preoperative work up of a soft tissue tumor includes magnetic resonance imaging
(MRI) or magnetic resonance angiography (MRA) and/or computed tomography (CT)
and/or ultrasonography (US) of the tumor site, followed by fine-needle aspiration (FNA),
core biopsy, and/or incisional biopsy [8]. In superficially located soft tissue tumors smaller
than 3 cm, and without clinical suspicion of malignancy, an excisional biopsy is per-
formed [9]. In case of a histological diagnosis of liposarcoma, a chest CT-scan and a bone
scan are performed to rule out metastatic disease [8]. We used the classification described
by Enzinger [3], and recognized four different subtypes: well-differentiated LPS (WDLPS),
myxoid LPS (MXLPS), pleiomorphic LPS (PMLPS), and dedifferentiated LPS (DDLPS).
Tumors were graded according to Coindre et al [10], and grade was assigned based on the
highest grade presented. Patients were clinically staged according to the latest AJCC
staging guidelines for sarcoma [11].
After preoperative work up, the tumor was resected with the intention to perform a wide
local resection. Resection margins were classified as microscopically involved if, on his-
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tologic examination, tumor cells were detected at the marked surface of the resection
specimen. In recent years, in cases of microscopic involvement of the margins (R1-resec-
tion), especially in high-grade tumors, high-dose adjuvant radiation therapy (50-70 Gy)
has been recommended [8]. Chemotherapy was only delivered to eligible patients who
participated in different chemotherapy protocols during this time period.
In primary LPS, the follow-up period was calculated from the time of histological diag-
nosis. In LPS, presenting with a recurrence, the follow-up period was measured from
the time of histological diagnosis of the recurrence. The local and distant recurrence
rates were calculated using the Kaplan-Meier method.
Epidemiologic data were analyzed using the Mann-Whitney U-test and Chi-square test.
Clinicopathological and treatment related factors were analyzed using a log-rank test for
local recurrence, disease-free and overall survival. A P value <0.05 was considered statis-




The study group was composed of 35 men (51%) and 34 women (49%). Fifty-two LPS
were primary tumors (75%). Seventeen patients presented with a local recurrence after
earlier attempts at definitive treatment at outside institutions (25%). In nine of them
(53%) it was the first or second recurrence, in four patients (24%), it was the third recur-
rence, in two patients (11%), it was the fourth recurrence, in one patient (6%), the sixth
recurrence, and one patient (6%) had a seventh recurrence. Overall, the median age at
presentation was 51 (range 11-80) years. The median age at presentation was not signifi-
cantly different in primary or recurrent LPS, 49 (range 11-80) years and 56 (range 35-80)
years, respectively.
Clinical characteristics
By far, most patients (n=57) presented with a palpable mass (83%), which in most of
them (n=46) was painless. At presentation, the median duration of symptoms was 6
months for primary LPS, and 3 months for recurrent LPS. There was no gender-related
difference.
The distribution of LPS according to anatomical site is shown in Fig. 1. The majority of
LPS was located in the extremities (n=43; 62%), especially the thigh (n=29; 42%). Al-
though 57 tumors (83%) were palpable on clinical examination, there were site-specific
differences. In the head/neck region, trunk and extremities, most LPS were palpable
(80%, 100%, 95%, respectively), whereas in retroperitoneum and buttock respectively
64% and 50% of the tumors, were undetectable on clinical examination. Overall, 61 LPS
were situated beneath the fascia (88%). The relation between tumor site and tumor depth
was highly statistically significant (P=0.002), with the highest proportion of superfi-
cially located tumors in the head/neck region and in the upper extremity, 60% and 40%,
respectively. In retroperitoneum, buttock and leg (nearly) all LPS were deeply seated
(Fig. 1).
Chapter 4 Prognostic factors in liposarcoma
40
Preoperative work up
Ultrasonography (US) of the tumor region was performed in 23 patients (33%). During
the operation, information from the US appeared to be correct in only 6 of these patients
(26%). CT-scan and MRI of the tumor region were performed in 40 patients (58%) and
29 patients (42%), respectively. Distant metastatic disease was excluded by plain chest
film (n=57; 83%), pulmonary CT-scan or MRI (n=48; 70%), and bone scan (n=37; 54%).
In 6 patients, the tumor was resected after only FNA (9%) and in 1 patient after core
biopsy (1%), whereas in the remaining 62 patients, the histological diagnosis was made
by biopsy (incisional: n=31 [45%] and excisional: n=16 [23%]) or tumor resection (n=15,
22%). Eleven of the 15 tumors that were resected without prior histological diagnosis
were recurrent LPS (73%). One patient had a primary LPS of the spermatic cord and was
treated by orchidectomy. One patient had a primary LPS in the lower extremity, which
was treated with surgical resection, followed by external beam radiation therapy. Two
patients had a retroperitoneal LPS, which was surgically resected, en block with the left
kidney and the left side of the colon in one, and en block with the left kidney in the other.
Treatment
Thirty-two patients were treated by surgical resection only (47%), 25 patients received
additional radiotherapy (36%), 3 patients had additional chemotherapy (4%), and the
remaining 9 patients (13%) were treated by a combined modality treatment of surgery,
radiotherapy, and chemotherapy.
A marginal resection was performed in 54 patients (78%), a radical resection in 13 pa-
tients (19%), and in the remaining 2 patients (3%), the tumor was resected intracapsularly.
Intraoperative tumor spill occurred in 3 patients (4%), 2 of who had a retroperitoneal
LPS, and one a LPS of the thigh.
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Figure 1. Distribution of LPS according to anatomical site (n=69).
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Radiotherapy was applied in 34 patients (49%), most often postoperatively (n=30; 88%).
Two patients with a LPS of the thigh received both pre- and postoperative external beam
radiation therapy (EBRT), one patient with a primary gluteal LPS received neoadjuvant
EBRT, followed by intraoperative radiation therapy (IORT) [12]. One patient with a sec-
ond recurrence of a MXLPS of the popliteal fossa, previously treated with surgery and 64
Gy EBRT, was treated with surgical resection and 25 Gy IORT [13]. Overall, the median
total radiation dose was 60 Gy, ranging from 25 (IORT)-70 Gy.
Only a small number of patients (n=12; 17%), who participated in different protocols,
received chemotherapy. Radiotherapy and/or chemotherapy related complications were
encountered in 17 of 37 patients (46%). By far, most were minor complications (ery-
thema, dermatitis, epidermolysis, mucositis, and wound complications). However, four
patients developed a neuropathy (11%), which was transient in two, but persisted in the
other two patients.
Limb salvage was achieved in 45 of 47 limbs (96%) involved (gluteal LPS included). In
one patient presenting with a recurrent LPS of the thigh, an exarticulation of the hip had
to be performed. One patient with a primary gluteal LPS had to be treated by hemipelvec-
tomy and intraoperative radiation therapy [12]. During follow-up, an additional patient
who developed a local recurrence could only be salvaged by a high exarticulation of the
lower limb, decreasing the cumulative limb salvage rate to 94%.
Histopathology
The revised histopathological diagnoses are presented in Fig. 2, which shows that nearly
half of the tumors were MXLPS, and that more than one third were WDLPS. For the
various anatomical sites, tumor size, as measured by the pathologist, is presented in Fig.
3. The largest tumors were encountered in the retroperitoneum (median diameter 25
[range 12-46] cm) and lower limb (median diameter 12 [range 2-40] cm). Twenty-four of
26 WDLPS (92%) were classified as grade I LPS, the other 2 as grade II (8%), 29 MXLPS
were classified as grade I (85%), and 5 MXLPS as grade II (15%). Three DDLPS were
grade III LPS (50%), whereas the other three were classified as grade II. Two of three
PMLPS were classified as grade II, the third as grade III. The relation between histologi-
cal subtype and tumor grade seemed to be highly significant (P<0.0001).
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Figure 2. Histological distribution of LPS (n=69).
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Overall, there was no statistically significant relation between anatomical site and tumor
grade (P=0.19), although retroperitoneal LPS had a significantly higher tumor grade
compared to LPS at other sites (P=0.02). According to the new AJCC staging guidelines
[10], 10 LPS were staged as stage Ia (14%), 3 LPS as stage Ib (4%), 52 LPS as stage IIa
(76%), and 4 LPS as stage III (6%). LPS of the retroperitoneum, buttock, and thigh had
significantly more often stage II and III (P=0.01). Microscopically, free margins (R0-
resection) were achieved in 53 patients (77%); in the other 16 patients (23%) margins
were microscopically involved (R1-resection). No patient had a macroscopic tumor left
behind (R2-resection).
Recurrence and Survival
The duration of follow-up for this cohort of patients ranged from 5 to 251 months with
median and mean follow-up of 79 and 87 months, respectively.
Local recurrence
During follow-up, 18 of 69 patients (26%) developed a local recurrence after 2-101 months.
A total of 28% of local recurrences was evident by 1 year, 44% by 2 years, 72% by 3 years,
78% by 4 years, and 89% by 5 years. There were two very late local recurrences after 81
and 101 months. Multiple recurrences were common and occurred in 67% of patients
who developed a local recurrence after initial presentation with a primary LPS, and in
83% of patients who presented with a recurrent LPS.
On univariate analysis, retroperitoneal localization was associated with a significantly
shorter local recurrence-free interval (Table 1, Fig. 4). Retroperitoneal LPS recurred after
a median recurrence-free interval of 48 months. At the end of the study period, five of
the patients who had had a retroperitoneal LPS had no signs of recurrent disease. Four
patients died from unresectable local recurrences in absence of distant metastases, and
Prognostic factors in liposarcoma Chapter 4
Figure 3. Tumor size according to anatomical site.
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one patient died from an unresectable local recurrence and metastases to the lung, verte-
brae, and soft tissues. One patient is still alive but has an unresectable local recurrence
without distant metastases and is likely to suffocate in the near future.
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Table 1. Local recurrence-free interval according to potential prognostic factors.
Clinicopathological factor RR 95% CI
Gender Male vs. female 0.69 0.27-1.74
Histological subtype WDLPS vs. all other subtypes 2.39 0.79-7.3
All other subtypes vs. DDLPS 1.04 0.14-7.8
Primary vs. recurrent presentation 1.36 0.51-3.63
Anatomical site All other sites vs. retroperitoneum 3.22* 1.21-8.6
Depth Superficial vs. deep 2.69 0.36-20.2
Type of resection R1 vs. marginal 1.01 0.32-3.18
R1 vs. radical 1.25 0.28-5.56
Tumor diameter ≤10 cm vs. 10-20 cm 1.64 0.53-5.07
≤10 cm vs. >20 cm 2.92 0.94-9.0
Grade I vs. II 1.11 0.32-3.85
I vs. III 2.05 0.27-15.6
Stage I vs. II 5.32 0.71-40.7
I vs. III 8.55 0.53-137
Treatment Surgery vs. surgery + radiotherapy 0.54 0.19-1.54
Surgery vs. surgery + chemotherapy 0.85 0.11-6.55
Surgery vs. surgery + radiotherapy +
chemotherapy 0a
* Significance, P< .05.
a Numbers too small to draw conclusions.
Figure 4. Local recurrence-free interval according to anatomical site.
Distant metastases
Within a range of 4-103 months, 11 patients (16%) developed distant metastases. Of these,
27% were evident by 1 year, 55% by 2 years, 82% by 3 years, and 91% by 5 years. One
44
patient developed distant metastases after 103 months. Four patients (36%) with distant
metastases also experienced a local recurrence. In three of them, the local relapse pre-
ceded the distant failure by a median interval of 47 (range 4-91) months. In one patient,
local and distant relapse occurred simultaneously.
The lung was the most common site for metastases (72%), followed by vertebrae (36%),
soft-tissues (27%), liver (18%), and brain (9%). None of the 26 WDLPS developed distant
metastases, whereas 3 out of 6 metastasizing MXLPS (50%) did so to the soft tissues.
Three patients (all MXLPS) developed extrapulmonary metastases only (soft tissue, spine,
and brain).
A univariate analysis of prognostic factors with regard to metastasis-free interval is pre-
sented in Table 2. Deep tumor location, DDLPS (Relative Risk [RR] 13.6), and tumor
grade II and III (RR 7.8 and 14.6, respectively) were associated with a significantly shorter
metastasis-free period (Fig. 5 a,b). After 5 years, DDLPS had a metastasis rate of 78%,
with a median metastasis-free interval of 20 months. After 5 years, grade I, II, and III
LPS had a metastasis rate of 8%, 49%, and 50%, respectively. The median metastasis-
free interval in grade II an III LPS was 36 and 20 months, respectively. The relative risk
of DDLPS was not influenced by tumor depth (RR 11.9, 95% CI: 3.49- 40.7), nor by grade
(RR 10.3, 95% CI: 3.01- 35.2). Tumor grade II and III lost significance, when adjusted for
dedifferentiated subtype (RR 2.82, 95%CI: 0.76- 10.5 and RR 1.45, 95%CI: 0.27- 7.9,
respectively). None of the superficially located tumors metastasized to distant sites.
Survival
A univariate analysis with regard to disease-free interval is presented in Table 3, demon-
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Table 2. (Distant) metastasis-free interval according to potential prognostic factors.
Clinicopathological factor RR 95% CI
Gender Male vs. female 0.36 0.10-1.37
Histological subtype All other subtypes vs. DDLPS 13.6* 4.0-47
Primary vs. recurrent presentation 0.28 0.04-2.15
Anatomical site All other sites vs. retroperitoneum 0.53 0.07-4.2
Depth Superficial vs. deep ∞*
Type of resection R1 vs. marginal 3.83 0.49-30.3
R1 vs. radical 1.57 0.10-25.1
Tumor diameter ≤ 10 cm vs. 10-20 cm 1.57 0.39-6.26
≤ 10 cm vs. > 20 cm 1.93 0.43-8.6
Grade I vs. II 7.81* 2.10-29.1
I vs. III 14.6* 2.67-80
I vs. II + III 9.01* 2.64-31
Stage I vs. II + III 0.66 0.17-2.49
Treatment Surgery vs. surgery + radiotherapy 0.34 0.07-1.66
Surgery vs. surgery + chemotherapy 1.23 0.15-10.0
Surgery vs. surgery + radiotherapy + 0.59 0.15-2.80
chemotherapy
* Significance, P< .05.
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strating a significantly longer disease-free interval in WDLPS (Fig 6), grade I LPS (Fig 7),
stage I LPS, and in tumors ≤10 cm. When corrected for tumor size and stage, WDLPS
still had a better disease-free interval (RR 4.4 and 3.6, respectively). When adjusted for
grade, WDLPS lost its significance (RR 2.7). Tumor grade I remained a significant factor
when adjusted for tumor size (RR 2.6), but lost independency when adjusted for histo-
logical subtype (RR 1.3) or stage (RR 1.7). Tumor stage I, corrected for histological subtype,
tumor grade or tumor size, lost significance (RR 6.9, 5.2, and 4.2, respectively). Tumor
size lost significance, when adjusted for grade (RR 1.96) or stage (RR1.74), but was not
influenced by histological subtype WDLPS (RR 4.2).
In univariate analysis, dedifferentiation, grade II and III, non-radical resection, and stage
II and III were associated with a worse disease-specific survival (Table 4). None of the
stage I patients died of the disease, but the numbers are too limited to reach statistical
significance. After correction for radicalness of resection, DDLPS (Fig 8a) and grade II-
III LPS (Fig 8b) continued to have a significantly worse disease-specific survival (RR 10.2
and 7.9, respectively), but when corrected for each other, both factors lost significance.
After a radical resection, no patient died of the disease.
Chapter 4 Prognostic factors in liposarcoma
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Table 3. Disease-free survival according to potential prognostic factors.
Clinicopathological factor RR 95% CI
Gender Male vs. female 0.56 0.25-1.25
Histological subtype WDLPS vs. PMLPS 2.80 0.31-25.1
WDLPS vs. MXLPS 3.21* 1.07-9.7
WDLPS vs. DDLPS 13.0 0.86-10.4
WDLPS vs. all other subtypes 3.88* 1.33-11.3
Primary vs. recurrent presentation 1.04 0.43-2.50
Anatomical Site All other sites vs. retroperitoneum 1.92 0.76-4.79
Depth Superficial vs. deep 3.91 0.53-28.9
Type of resection R1 vs. marginal 1.48 0.55-3.95
R1 vs. radical 0.26 0.03-2.20
Tumor diameter ≤ 10 cm vs. 10-20 cm 1.92 0.74-4.99
≤ 10 cm vs. > 20 cm 3.03* 1.14-8.09
Grade I vs. II 2.80* 1.14-6.87
I vs. III 5.39* 1.56-18.6
I vs. II + III 3.27* 1.47-7.3
Stage I vs. II 7.10 0.96-52.8
I vs. III 23.9* 2.48-229
I vs. II + III 7.79* 1.05-57.6
Treatment Surgery vs. surgery + radiotherapy 0.69 0.28-1.75
Surgery vs. surgery + chemotherapy 2.21 0.50-9.8
Surgery vs. surgery + radiotherapy + 0.97 0.63-2.44
chemotherapy
* Significance, P< .05.
Figure 6. Disease-free survival according to histological subtype.
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Table 4. Overall (disease-specific) survival according to potential prognostic factors.
Clinicopathological factor RR 95% CI
Gender Male vs. female 0.41 0.13-1.33
Histological subtype all other subtypes vs. DDLPS 14.4* 4.72-44.1
Primary vs. recurrent presentation 0.50 0.11-2.28
Anatomical Site All other sites vs. retroperitoneum 2.76 0.85-8.9
Depth Superficial vs. deep ∞
Type of resection R1 vs. marginal 2.34 0.52-10.6
R1 vs. radical 0*
Tumor diameter ≤ 10 cm vs. 10-20 cm 1.91 0.51-7.1
≤ 10 cm vs. > 20 cm 2.60 0.65-10.4
Grade I vs. II 8.01* 2.26-28.4
I vs. III 31.7* 7.1-142
I vs. II + III 10.7* 3.29-34.6
Stage I vs. II + III ∞
Treatment Surgery vs. surgery + radiotherapy 1.43 0.41-5.0
Surgery vs. surgery + chemotherapy 1.95 0.23-16.7
Surgery vs. surgery + radiotherapy + 2.34 0.38-7.4
chemotherapy
* Significance, P< .05.
Figure 7, Disease-free survival according to tumor grade.
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Discussion
Liposarcoma (LPS) is the second or third most common soft tissue sarcoma (STS) of
adult life, and the incidence is estimated at 10-20% of all STS [1,2,3,4]. This tumor is
primarily a tumor of adult life, and generally shows a slight preference for the male sex
[7,14,15]. In this series, the median age at presentation with a primary or recurrent LPS
was 49 and 56 years, respectively, and the male/female ratio was 1.03. Liposarcoma most
often occur in the lower extremity (13-68%), and the retroperitoneum is the second most
common site (10-36%) [7,16,17]. This was confirmed in our series in which 38 of 69 LPS
(55%) were situated in the lower extremity, primarily in the thigh (n=29). The
retroperitoneum was the second most frequent anatomical site (16%). Characteristically,
most LPS are deeply seated, and the majority seems to take origin from large intermus-
cular connective tissue spaces. Localization in the subcutaneous tissue is rare. However,
noteworthy exceptions are the shoulder and head/neck area where tumors of smaller
size, and shorter duration of symptoms, may extend into subcutaneous fat [18,19]. In
this series, 8 of 69 LPS (12%) were subcutaneously seated, with the highest relative
Figure 8. (A) Disease-specific survival according to histological subtype. (B) Disease-specific survival
according to tumor grade.
A
B
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frequency in the head/neck region (60%), and the lowest in lower extremity, buttock,
and retroperitoneum (5%, 0%, 0%) (Fig. 1).
It is difficult to compare the distribution of histological subtypes in the literature be-
cause different classifications have been used and anatomical distributions often vary.
Undoubtedly, the myxoid type is by far the most common LPS. It is described most
frequently in the literature [7,14,19], and was present in almost half of our patients (49%).
The distribution of the other histological subtypes was in accordance with the series
from the University of Texas M.D. Anderson Cancer Center (MDACC), published by
Evans [7]. The relative frequency of PMLPS in our and the MDACC series was relatively
low (4-5%), compared to some reports in the literature [2,14]. However, the latter series,
which report 23%-26% PMLPS, have a different distribution of anatomical sites and/or
did not recognize the dedifferentiated subtype.
After 5 years of follow-up, the overall local recurrence rate in the present series was 27%,
which seems to be in accordance with other reports, although the figures should be
interpreted with caution because length of follow-up and distribution of histological
subtypes and anatomical sites vary widely [2,15,17]. One of the highest local recurrence
rates (85%) is reported in a series by Evans, comparable with this present series, but that
study had a much longer follow-up with a minimum of 10 years [7]. This very long fol-
low-up may be responsible for the high local recurrence rate because in LPS, which is
different from other STS, (very) late recurrences are common [2,17,19]. In this series,
only 44% of all local recurrences were evident by 2 years, whereas 11% occured after 5
years, the latest of which even occurered 8.5 years after treatment. From the literature,
histological subtype (DDLPS and PMLPS) [19,20], retroperitoneal localization [15,21],
recurrent presentation [19,21], and involved surgical margins [17,19] have been reported
as independent negative prognostic factors with regard to local recurrence. In the current
series, retroperitoneal localization was the most important significant factor impairing
the local recurrence-free interval (Table 1). No local recurrences were encountered after
multimodality treatment (surgery, radiotherapy, and chemotherapy), but numbers were
too small to draw conclusions. Histological subtype, tumor grade and size, recurrent
presentation, margin status, and stage were not significant prognostic factors for local
control.
Once LPS recurred, multiple recurrences were common (overall 72%). LPS tend to recur
uncontrollably, especially in the retroperitoneum, and may be fatal through local effects,
as reported by others [22,23]. Dedifferentiation in recurrence is reported in well-differen-
tiated retroperitoneal LPS and is associated with a poor outcome [6,7,15,22]. This feature
was encountered in 2 of 18 local recurrences (11%), both of which were retroperitoneal
WDLPS. Both patients died from an unresectable local recurrence, in the absence of
distant metastases.
After 5 years of follow-up, the overall metastasis rate was 16%. Most metastases became
evident within the first three postoperative years (72%), as reported by others [2,19]. Late
distant failures appeared to be relatively rare because nearly all metastases were evident
by 5 years. As expected, the lung was the most common site for metastases (72%). This
relative frequency is comparable with the results of Kindblom [6], but is high compared
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to others (38%-57%) [2,7]. The high tendency of MXLPS to metastasize to extrapulmonary
soft-tissue sites, reported in the literature (38-88%) [2,7,19,20,24], was confirmed in our
series, in which 50% of metastasizing MXLPS did so to soft tissues. WDLPS did not
metastasize to distant sites.
From the literature, high tumor grade [2], pleomorphic subtype [19,20], round cell subtype
(a poorly differentiated form of MXLPS) [24,25], and tumor necrosis [2] have been re-
ported as independent factors associated with impaired metastasis-free interval. As shown
in table 2, and Fig. 5 a,b, DDLPS, tumor grade II and III, and deep tumor location were
significant determinants of metastatic outcome in the present series. After 5 years, grade
II and III LPS had the highest metastatic rate (49 and 50%, respectively), with the short-
est median metastasis-free interval (≤ 3 years). Superficially located tumors did not
metastasize.
Because several different classification systems for LPS have been used, it is very diffi-
cult to compare survival data from the literature. Reported independent negative prog-
nostic factors are high tumor grade [21,26], tumor necrosis [2], tumor size ≥ 5 cm [19,26],
tumor size ≥ 10 cm [21], histological subtype (PMLPS, DDLPS, round cell MXLPS)
[14,18,19,20,24,25,27], recurrent presentation [21], and retroperitoneal localization
[14,15,17,21]. In the current series, four factors (histological subtype, tumor size, tumor
grade, and tumor stage) were significantly associated with disease-free survival (Table 3,
Fig. 6, 7). Patients with WDLPS, tumors ≤ 10 cm, grade I LPS, and AJCC stage I LPS had
a significantly longer disease-free survival, but these factors appeared to be associated
with each other.
Three factors that significantly determined disease-specific survival were histological
subtype, tumor grade, and type of resection (Table 4, Fig. 8 a,b). DDLPS, grade II-III, and
non-radical resections had a significantly worse disease-specific survival. After radical
resection, no patient died of the disease. Even when adjusted for type of resection, DDLPS
and grade II-III LPS continued to have a significantly worse disease-specific survival,
although both factors were associated with each other.
In the current series, we did not study the influence of the round cell subtype, a poorly
differentiated variation of MXLPS, because round cell LPS was not recognized as a sepa-
rate entity. Although strict criteria defining the prognostic significance of the round cell
component in MXLPS have not been established [27], there are reports showing that a
round cell component varying from >25% to even >5% is associated with a poor progno-
sis [25,28]. Tumor necrosis was also not analyzed as a separate prognostic factor. How-
ever, this factor, together with tumor differentiation and mitosis count, is one of the
cornerstones of tumor grade classification, as described by Coindre et al [10]. The prog-
nostic importance of retroperitoneal localization could not be demonstrated in this se-
ries, but this may be a time-dependent issue, because at the end of the study period, 4 of
11 patients (45%) with retroperitoneal LPS had died from their disease; 1 patient had an
unresectable local recurrence at the end of the study period, which will be fatal in the
near future (9%). Moreover, in those patients with retroperitoneal STS without evidence
of disease, the duration of follow-up was relatively short.
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Conclusion
This series of 69 consecutive patients with completely resected, AJCC stage I-III LPS
confirms that liposarcoma is a quite heterogeneous disease, and that its outcome is de-
termined to a significant degree by histological subtype, grade, size, stage, depth, and
type of resection. Compared with other soft tissue sarcomas, LPS has a relatively mild
biological behavior, with the exception of large, deeply located, dedifferentiated and/or
grade II-III LPS. With regard to local failure, retroperitoneal localization was an addi-
tional negative prognostic factor. However, in contrast to some reports in the literature,
we were not (yet) able to demonstrate a significant influence of retroperitoneal localiza-
tion on survival.
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